SG11201401458UA - Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability - Google Patents
Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeabilityInfo
- Publication number
- SG11201401458UA SG11201401458UA SG11201401458UA SG11201401458UA SG11201401458UA SG 11201401458U A SG11201401458U A SG 11201401458UA SG 11201401458U A SG11201401458U A SG 11201401458UA SG 11201401458U A SG11201401458U A SG 11201401458UA SG 11201401458U A SG11201401458U A SG 11201401458UA
- Authority
- SG
- Singapore
- Prior art keywords
- semaphorin
- modulation
- binding molecules
- brain barrier
- blood brain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161545809P | 2011-10-11 | 2011-10-11 | |
| US201161555726P | 2011-11-04 | 2011-11-04 | |
| US201261593641P | 2012-02-01 | 2012-02-01 | |
| PCT/US2012/059757 WO2013055922A1 (en) | 2011-10-11 | 2012-10-11 | Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201401458UA true SG11201401458UA (en) | 2014-07-30 |
Family
ID=48082436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201401458UA SG11201401458UA (en) | 2011-10-11 | 2012-10-11 | Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20130095118A1 (en) |
| EP (1) | EP2766093B1 (en) |
| JP (2) | JP6395606B2 (en) |
| KR (1) | KR101999872B1 (en) |
| CN (2) | CN104168956A (en) |
| AU (1) | AU2012322721B2 (en) |
| BR (1) | BR112014008885B1 (en) |
| CA (1) | CA2851805C (en) |
| DK (1) | DK2766093T3 (en) |
| EA (1) | EA029023B1 (en) |
| ES (1) | ES2669209T3 (en) |
| IL (1) | IL232072B (en) |
| MX (1) | MX353550B (en) |
| PT (1) | PT2766093T (en) |
| SG (1) | SG11201401458UA (en) |
| WO (1) | WO2013055922A1 (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2427212T3 (en) | 2009-05-08 | 2017-12-04 | Vaccinex Inc | ANTI-CD100 ANTIBODIES AND PROCEDURES FOR USE THEREOF |
| US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| BR112015032690B1 (en) | 2013-06-25 | 2020-03-10 | Vaccinex, Inc. | USE OF SEMAPHORIN-4D INHIBITOR MOLECULES IN COMBINATION WITH AN IMMUNOMODULATIVE THERAPY TO INHIBIT TUMORAL GROWTH AND METASTASIS |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) * | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| EP3881857A1 (en) | 2016-02-18 | 2021-09-22 | The Penn State Research Foundation | Generating gabaergic neurons in brains |
| FI3445397T3 (en) | 2016-04-22 | 2023-02-20 | Vaccinex Inc | Integral membrane protein display on poxvirus extracellular enveloped virions |
| US20190169606A1 (en) | 2016-08-02 | 2019-06-06 | Vaccinex, Inc. | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
| IL265352B1 (en) * | 2016-09-13 | 2024-01-01 | Angiocrine Bioscience Inc | Blood-brain barrier comprising engineered endothelial cells |
| JP2020510845A (en) * | 2017-02-22 | 2020-04-09 | バクシネックス インコーポレーティッド | Early detection method of glial cell activation in neurodegenerative disease or neuroinflammatory disease |
| SG11201909466RA (en) | 2017-05-05 | 2019-11-28 | Vaccinex Inc | Human anti-semaphorin 4d antibody |
| CA3087869A1 (en) * | 2018-02-02 | 2019-08-08 | The Penn State Research Foundation | Methods and materials for treating brain injuries |
| KR20210144795A (en) * | 2019-03-29 | 2021-11-30 | 추가이 세이야쿠 가부시키가이샤 | Inhibitors of BBB Function Decrease Containing Anti-IL-6 Receptor Antibodies |
| US11597765B2 (en) | 2020-06-25 | 2023-03-07 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules for the treatment of Rett syndrome |
| EP3973979A1 (en) * | 2020-09-25 | 2022-03-30 | The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth | A tight junction (zonulae occludentes) protein for use in treating or preventing epilepsy |
| CN113456813A (en) * | 2021-07-26 | 2021-10-01 | 苏州大学 | Application of Semaphorin7A monoclonal antibody in preparation of medicines for treating thrombus and cerebrovascular diseases |
| WO2023012314A1 (en) * | 2021-08-05 | 2023-02-09 | Lifearc | Anti-plexin-b1 antibodies |
| CN114539204B (en) * | 2022-03-23 | 2023-08-22 | 福建金兰厚普生物科技有限公司 | Hexokinase inhibitor and synthesis method and application thereof |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5070192A (en) | 1988-03-23 | 1991-12-03 | The Johns Hopkins University | Cloned human topoisomerase i: cdna expression, and use for autoantibody detection |
| SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
| US6497872B1 (en) | 1991-07-08 | 2002-12-24 | Neurospheres Holdings Ltd. | Neural transplantation using proliferated multipotent neural stem cells and their progeny |
| FR2686087A1 (en) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | NOVEL LYMPHOCYTATIC ANTIGEN, CORRESPONDING ANTIBODIES AND THEIR APPLICATIONS. |
| US5639856A (en) | 1993-09-13 | 1997-06-17 | The Regents Of The University Of California | Semaphorin gene family |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6576754B2 (en) | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
| BRPI9809387B8 (en) | 1997-04-07 | 2021-05-25 | Genentech Inc | humanized anti-human vascular endothelial growth factor antibody and composition comprising it |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| AU6897998A (en) | 1997-04-11 | 1998-11-11 | Dendreon Corporation | Composition and method for inducing an immune response against tumour-rela ted antigens |
| EP0892047A3 (en) * | 1997-07-09 | 2000-03-08 | Hoechst Marion Roussel Deutschland GmbH | Human and murine semaphorin L |
| US5968829A (en) | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
| US6638501B1 (en) | 1997-09-29 | 2003-10-28 | Neurospheres Holdings Ltd. | Use of multipotent neural stem cell progeny to augment non-neural tissues |
| US5958767A (en) | 1998-08-14 | 1999-09-28 | The Children's Medical Center Corp. | Engraftable human neural stem cells |
| WO2000028016A1 (en) | 1998-11-10 | 2000-05-18 | University Of Rochester | T cells specific for target antigens and methods and vaccines based thereon |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| JP3787473B2 (en) | 1999-11-30 | 2006-06-21 | 独立行政法人科学技術振興機構 | Semaphorin receptor |
| US6635742B1 (en) | 2000-01-25 | 2003-10-21 | Nuvelo, Inc. | Antibodies specific for semaphorin-like polypeptides |
| WO2001046384A2 (en) | 1999-12-23 | 2001-06-28 | Cornell Research Foundation, Inc. | A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells |
| CN1329060A (en) | 2000-06-19 | 2002-01-02 | 上海博德基因开发有限公司 | A novel polypeptide-human semaphorin protien 9 and polynucleotide for coding this polypeptide |
| WO2002102972A2 (en) | 2001-06-20 | 2002-12-27 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| US20080219974A1 (en) | 2002-03-01 | 2008-09-11 | Bernett Matthew J | Optimized antibodies that target hm1.24 |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| EP1365018A1 (en) | 2002-05-23 | 2003-11-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | CD100 semaphorin in myelination |
| BR0311471A (en) | 2002-05-30 | 2007-04-27 | Macrogenics Inc | anti-cd16a antibody, and methods for reducing a deleterious immune response in a mammal and treating a deleterious immune response in a mammal |
| US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
| EP1442749A1 (en) * | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
| CN1788017B (en) * | 2003-02-10 | 2013-04-24 | to-BBB控股股份有限公司 | Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions |
| ME00425B (en) | 2003-05-30 | 2011-10-10 | Genentech Inc | Treatment with anti-vegf antibodies |
| CA2538763C (en) | 2003-09-11 | 2015-05-05 | Critical Therapeutics, Inc. | Monoclonal antibodies against hmgb1 |
| NZ547591A (en) | 2003-12-04 | 2009-11-27 | Vaccinex Inc | Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells |
| US20050233960A1 (en) | 2003-12-11 | 2005-10-20 | Genentech, Inc. | Methods and compositions for inhibiting c-met dimerization and activation |
| ZA200701656B (en) | 2004-08-05 | 2008-09-25 | Genentech Inc | Humanized anti-cment antagonists |
| US20060147449A1 (en) | 2004-11-15 | 2006-07-06 | Brass Lawrence F | Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses |
| EP1871484A2 (en) | 2005-04-07 | 2008-01-02 | Chiron Corporation | Sema4d in cancer diagnosis, detection and treatment |
| AU2006314528A1 (en) | 2005-11-16 | 2007-05-24 | Novartis Ag | Biomarkers for anti-nogo-A antibody treatment in spinal cord injury |
| JP2007308465A (en) | 2006-05-15 | 2007-11-29 | Boehringer Ingelheim Internatl Gmbh | Method for treatment of inflammatory disease, autoimmune disease or bone resorption abnormality |
| US8257706B2 (en) | 2006-08-25 | 2012-09-04 | Seattle Genetics, Inc. | CD30 binding agents and uses thereof |
| US9382327B2 (en) | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
| ES2635317T3 (en) * | 2007-01-05 | 2017-10-03 | University Of Zurich | Anti-beta-amyloid antibody and its uses |
| WO2008100995A1 (en) * | 2007-02-14 | 2008-08-21 | Vaccinex, Inc. | Humanized anti-cd100 antibodies |
| WO2008103392A2 (en) | 2007-02-21 | 2008-08-28 | Vaccinex, Inc. | Modulation of nkt cell activity with antigen-loaded cdid molecules |
| KR101642846B1 (en) | 2007-12-26 | 2016-07-26 | 백시넥스 인코포레이티드 | Anti-C35 antibody combination therapies and methods |
| PE20091378A1 (en) | 2008-01-10 | 2009-10-14 | Genentech Inc | PLEXIND1 AGONIST POLYPEPTIDES |
| DK2427212T3 (en) * | 2009-05-08 | 2017-12-04 | Vaccinex Inc | ANTI-CD100 ANTIBODIES AND PROCEDURES FOR USE THEREOF |
| CA3017298C (en) | 2009-05-15 | 2021-09-28 | Irx Therapeutics, Inc. | Compositions comprising primary cell-derived biologics for enhancing immune responses in patients |
| JP5500944B2 (en) | 2009-10-29 | 2014-05-21 | 三菱電機株式会社 | Cooker |
| AU2011267869A1 (en) | 2010-06-14 | 2013-01-10 | Vaccinex, Inc. | Anti-VEGF antibodies and uses thereof |
| WO2012031099A2 (en) | 2010-09-02 | 2012-03-08 | Vaccinex, Inc. | Anti-cxcl13 antibodies and methods of using the same |
| JP5925768B2 (en) | 2011-05-13 | 2016-05-25 | 国立大学法人 東京医科歯科大学 | Bone formation promoter |
| US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
| CA2865928C (en) | 2012-03-02 | 2021-02-16 | Vaccinex, Inc. | Cxcl13 antagonist for the treatment of sjogren's syndrome |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| CA2899344C (en) | 2013-01-31 | 2022-11-08 | Vaccinex, Inc. | Methods for increasing immunoglobulin a levels |
| US9371352B2 (en) | 2013-02-08 | 2016-06-21 | Vaccinex, Inc. | Modified glycolipids and methods of making and using the same |
| BR112015032690B1 (en) | 2013-06-25 | 2020-03-10 | Vaccinex, Inc. | USE OF SEMAPHORIN-4D INHIBITOR MOLECULES IN COMBINATION WITH AN IMMUNOMODULATIVE THERAPY TO INHIBIT TUMORAL GROWTH AND METASTASIS |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| FI3445397T3 (en) | 2016-04-22 | 2023-02-20 | Vaccinex Inc | Integral membrane protein display on poxvirus extracellular enveloped virions |
| US20190169606A1 (en) | 2016-08-02 | 2019-06-06 | Vaccinex, Inc. | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
| JP2020510845A (en) | 2017-02-22 | 2020-04-09 | バクシネックス インコーポレーティッド | Early detection method of glial cell activation in neurodegenerative disease or neuroinflammatory disease |
-
2012
- 2012-10-11 US US13/649,651 patent/US20130095118A1/en not_active Abandoned
- 2012-10-11 EA EA201490768A patent/EA029023B1/en not_active IP Right Cessation
- 2012-10-11 PT PT128396017T patent/PT2766093T/en unknown
- 2012-10-11 BR BR112014008885-3A patent/BR112014008885B1/en active IP Right Grant
- 2012-10-11 CA CA2851805A patent/CA2851805C/en active Active
- 2012-10-11 CN CN201280059376.9A patent/CN104168956A/en active Pending
- 2012-10-11 CN CN201910351743.6A patent/CN110105452A/en active Pending
- 2012-10-11 DK DK12839601.7T patent/DK2766093T3/en active
- 2012-10-11 MX MX2014004457A patent/MX353550B/en active IP Right Grant
- 2012-10-11 JP JP2014535877A patent/JP6395606B2/en active Active
- 2012-10-11 SG SG11201401458UA patent/SG11201401458UA/en unknown
- 2012-10-11 AU AU2012322721A patent/AU2012322721B2/en active Active
- 2012-10-11 EP EP12839601.7A patent/EP2766093B1/en active Active
- 2012-10-11 KR KR1020147012547A patent/KR101999872B1/en active IP Right Grant
- 2012-10-11 ES ES12839601.7T patent/ES2669209T3/en active Active
- 2012-10-11 WO PCT/US2012/059757 patent/WO2013055922A1/en active Application Filing
-
2014
- 2014-04-10 IL IL232072A patent/IL232072B/en active IP Right Grant
-
2017
- 2017-06-30 JP JP2017129377A patent/JP2017193569A/en active Pending
-
2019
- 2019-06-06 US US16/433,496 patent/US11534488B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014530239A (en) | 2014-11-17 |
| EA201490768A1 (en) | 2014-09-30 |
| MX2014004457A (en) | 2014-06-05 |
| BR112014008885B1 (en) | 2021-02-17 |
| EA029023B1 (en) | 2018-01-31 |
| IL232072A0 (en) | 2014-05-28 |
| AU2012322721A1 (en) | 2013-05-16 |
| EP2766093A1 (en) | 2014-08-20 |
| ES2669209T3 (en) | 2018-05-24 |
| EP2766093B1 (en) | 2018-02-21 |
| US11534488B2 (en) | 2022-12-27 |
| US20130095118A1 (en) | 2013-04-18 |
| CN104168956A (en) | 2014-11-26 |
| JP6395606B2 (en) | 2018-09-26 |
| MX353550B (en) | 2018-01-18 |
| PT2766093T (en) | 2018-05-18 |
| IL232072B (en) | 2021-01-31 |
| DK2766093T3 (en) | 2018-06-06 |
| EP2766093A4 (en) | 2015-03-25 |
| KR20140076616A (en) | 2014-06-20 |
| AU2012322721B2 (en) | 2016-05-05 |
| KR101999872B1 (en) | 2019-07-12 |
| US20190358321A1 (en) | 2019-11-28 |
| WO2013055922A1 (en) | 2013-04-18 |
| CN110105452A (en) | 2019-08-09 |
| CA2851805A1 (en) | 2013-04-18 |
| CA2851805C (en) | 2021-12-28 |
| BR112014008885A2 (en) | 2017-04-18 |
| JP2017193569A (en) | 2017-10-26 |
| NZ623856A (en) | 2016-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL232072A0 (en) | Use of semaphorin - 4d binding molecules for modulation of blood brain barrier permeability | |
| HK1204267A1 (en) | Method of enhancing efficacy of blood transfusions | |
| EP2274007A4 (en) | Modulation of blood brain barrier permeability | |
| HK1203977A1 (en) | Enhancement of transport of therapeutic molecules across the blood brain barrier | |
| IL227698B (en) | Compounds and methods for kinase modulation and indications therefor | |
| EP2887873A4 (en) | Medical procedure localizing aid | |
| EP2926853A4 (en) | Filter syringe | |
| AP2015008266A0 (en) | 1L-18 binding molecules | |
| IL237617A0 (en) | Methods for increasing brain functionality using 2-fucosyl-lactose | |
| EP2839286A4 (en) | Compounds and methods for preparation of conjugate reagents | |
| EP2822647A4 (en) | Selective modulation of renal nerves | |
| EP2713932A4 (en) | Self-sealing filter for sterilization | |
| IL234813A0 (en) | Methods for increasing efficacy of cd37-based therapy | |
| EP2852403A4 (en) | Methods for modification of tissues | |
| GB201207543D0 (en) | Treatment of transfusion blood | |
| EP2554189A4 (en) | Blood treatment filter | |
| EP2906268A4 (en) | Infusion system disposable alignment system | |
| EP2822574A4 (en) | Methods for modulation of phosphorus and fgf23 | |
| EP2922585A4 (en) | Adsorbent for dialysis | |
| GB201320155D0 (en) | Magnetic treatment of fluids | |
| IL237229A0 (en) | Methods for treatment of cancer using lipoplatin | |
| FI3473276T3 (en) | Techniques for treatment of abscesses | |
| HK1171872A1 (en) | Modulation method of polarization differential pulse position | |
| GB2500294B (en) | Filter Aid | |
| GB201206324D0 (en) | Methods of treatment |